To continue reading this article, sign up for FREE to
Membership is FREE
and provides you with
instant access
to email newsletters, digital publications, our full content catalogue & more...
Codexis Enters into Research Collaboration with Schering-Plough
Codexis, Inc. has announced that it has signed a research agreement with Schering-Plough Corporation to develop a synthetic process for use by Schering-Plough.
The collaboration will focus on improving biocatalyst productivity using Codexis' proprietary MolecularBreeding™ pharmaceutical process re-engineering platform.
Codexis will receive research funding and milestone payments upon completion of certain objectives of the research.
"We are pleased to add Schering-Plough to our list of industry-leading pharmaceutical partners," said Alan Shaw, Ph.D., Codexis President and Chief Executive Officer.
"We are delighted to see a growing number of major pharmaceutical companies recognizing the competitive advantage and cost-savings value that Codexis' technology brings to the manufacturing process for clinical-scale production and product commercialization, and look forward to continued adoption of our technology across the pharmaceutical industry."
Add Technology Networks as a preferred Google source to see more of our trusted coverage.
